Atrial fibrillation (AF), which affects approximately 3-6 million people in the United States, is a risk factor for thromboembolic events including stroke, cardiovascular events, and death. This ...

Karen L. Hassenplug, Pharm.D.; Jill S. Burkiewicz, Pharm.D., BCPS; Terri L. Jackson, Ph.D., B.S.Pharm.; Laura R. Peppers, Pharm.D., BCPS Identifying baseline ...

Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrial fibrillation, but this therapy ...

Many patients requiring pacemaker or implantable cardioverter–defibrillator (ICD) surgery are taking warfarin. For patients at high risk for thromboembolic events, guidelines recommend bridging ...

(UPDATED) To help manage thrombotic risk after transcatheter mitral valve replacement (TMVR), clinicians should consider routine use of oral anticoagulation and regular clinical and imaging follow-up, ...

For decades now, stroke prevention in patients with atrial fibrillation has largely consisted of chronic oral anticoagulation, often with no end in sight. But a growing number of experts are asking: ...

Please provide your email address to receive an email when new articles are posted on . In patients with atrial fibrillation with a stent planted at least 1 year prior, oral anticoagulation ...

This study included only human randomised controlled trials (RCTs) and clinical controlled trials (CCTs). To be included studies had to include patients prescribed oral anticoagulant therapy (OAT) ...

In this session, data were presented from 3 separate trials that focused on potential ways to reduce the risk for bleeding in patients who require anticoagulation therapy, including the use of genetic ...

Patients with newly diagnosed psoriatic arthritis have a higher risk of CVD. Resuming antithrombotic therapy with in patients with atrial fibrillation and a serious gastrointestinal bleed results in ...